[A Case of Metastatic Recurrent Breast Cancer Successfully with Olaparib in Late Line Therapy].

Abstract

A 44-years-old woman who underwent bilateral mastectomy was treated with chemotherapy after axillary lymph nodes and liver metastases recurrence. She was referred to our hospital for BRCA1/2 germline test and the test revealed BRCA2 pathogenic mutation. Before the administration of olaparib as the fourth-line therapy, liver dysfunction, caused by extensive liver metastasis, was observed. The liver damage improved, and tumor markers decreased immediately as shown in the blood test and CT examination results after 2 months; indicating marked reduction of liver metastasis. In the OlympiAD trial, the patients received olaparib as either the first-, second- or third-line treatment; however, few data on the efficacy of olaparib in the patients, as a late line treatment, were reported. In this article, we report a case of a woman in whom olaparib was used as the fourth-line treatment for metastatic recurrent breast cancer. A high therapeutic effect was obtained and the quality of life has been maintained in her for the past 1 year.

• Authors: Misao Soyama, Tomonari Kunihisa, Natsumi Shimada, Haruna Suzuki, Yuna Ookawa, Aoi Okamoto, Mayuko Yamamoto, Mayuko Miki, Sachiko Mizumoto, Motoi Baba, Hirokazu Tanino
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 48 Issue 9 Pg. 1153-1155 (Sep 2021) ISSN: 0385-0684 [Print] Japan
• PMID: 34521794 (Publication Type: Case Reports, Journal Article)

Chemical References

• Phthalazines
• Piperazines
• olaparib

Topics

• Adult
• Breast Neoplasms (drug therapy)
• Female
• Germ-Line Mutation
• Humans
• Mastectomy
• Neoplasm Recurrence, Local
• Phthalazines
• Piperazines
• Quality of Life